يعرض 81 - 100 نتائج من 18,345 نتيجة بحث عن '(( 50 ((((ns decrease) OR (we decrease))) OR (a decrease)) ) OR ( 5 cm decrease ))', وقت الاستعلام: 0.94s تنقيح النتائج
  1. 81
  2. 82

    EB (Ethyl Butyrate) as a Cosolvent of Electrolyte Tuning an Ultrathin CEI Membrane for Improving the Ultralow-Temperature Behaviors of LiNi<sub>0.8</sub>Co<sub>0.1</sub>Mn<sub>0.1<... حسب Lucheng Li (13753395)

    منشور في 2023
    "…Adding lithium difluorophosphate into the original electrolyte results in outstanding eletrochemical performances among low temperatures, as documented in our earlier published work; therefore, to be able to gain more stability in low-temperature performances, in this work, a kind of linear carboxylate cosolvent, EB (ethyl butyrate), is introduced, which has low viscosity (0.639 mPa s), high ion conductivity (5.18 mS cm<sup>–1</sup>), and ultralow melting point (−93 °C). …"
  3. 83

    EB (Ethyl Butyrate) as a Cosolvent of Electrolyte Tuning an Ultrathin CEI Membrane for Improving the Ultralow-Temperature Behaviors of LiNi<sub>0.8</sub>Co<sub>0.1</sub>Mn<sub>0.1<... حسب Lucheng Li (13753395)

    منشور في 2023
    "…Adding lithium difluorophosphate into the original electrolyte results in outstanding eletrochemical performances among low temperatures, as documented in our earlier published work; therefore, to be able to gain more stability in low-temperature performances, in this work, a kind of linear carboxylate cosolvent, EB (ethyl butyrate), is introduced, which has low viscosity (0.639 mPa s), high ion conductivity (5.18 mS cm<sup>–1</sup>), and ultralow melting point (−93 °C). …"
  4. 84
  5. 85
  6. 86
  7. 87
  8. 88

    Discovery of New Inhibitors of Hepatitis C Virus NS3/4A Protease and Its D168A Mutant حسب Ittipat Meewan (7455041)

    منشور في 2019
    "…Several drugs targeting the protease have been developed, but drug-resistant mutant strains emerged. Here, we screened a library and synthesized a novel class of small molecules based on a tryptophan derivative scaffold identified as HCV NS3/4A protease inhibitors that are active against both wild type and mutant form of the protease. …"
  9. 89
  10. 90
  11. 91
  12. 92
  13. 93
  14. 94
  15. 95
  16. 96
  17. 97
  18. 98
  19. 99
  20. 100